Literature DB >> 11248289

The CC chemokines MDC and TARC induce platelet activation via CCR4.

S Abi-Younes1, M Si-Tahar, A D Luster.   

Abstract

While chemokines have received considerable attention for their role in leukocyte chemotaxis, their effects on platelets have not been well described. We found that two CC chemokine receptor 4 (CCR4) ligands, macrophage-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC) induce concentration-dependent platelet aggregation and calcium flux. Flow cytometric analysis revealed the expression of CCR4 on platelets and a monoclonal antibody (mAb) to CCR4 inhibited MDC- and TARC-induced platelet aggregation, confirming that this effect is mediated through their common receptor CCR4. MDC fully desensitized TARC-induced calcium mobilization in platelets, while TARC was unable to completely desensitize a subsequent MDC response, which is similar to observations made in Th2 CD4(+) lymphocytes and CCR4-transfected cells. Aspirin (ASA) treatment of platelets allowed reversible primary aggregation but inhibited irreversible complete aggregation, suggesting that MDC- and TARC-induced full platelet aggregation is dependent on cyclooxygenase metabolites of arachidonic acid. MDC and TARC were unable to induce platelet aggregation and platelet secretion in washed human platelets, even though they induced a calcium flux, suggesting that plasma components are required for MDC- and TARC-induced platelet aggregation. Since Th2-type cytokines induce the release of MDC and TARC from cells and the expression of these chemokines is increased in Th2-type inflammation, we hypothesize that MDC and TARC may play a role in platelet activation seen in Th2 diseases, such as asthma and atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248289     DOI: 10.1016/s0049-3848(00)00402-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  22 in total

1.  Elevated serum levels of CCL17 correlate with increased peripheral blood platelet count in patients with active tuberculosis in China.

Authors:  Yonghong Feng; Hongyun Yin; Guangliang Mai; Ling Mao; Jun Yue; Heping Xiao; Zhongyi Hu
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

Review 2.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

3.  CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function.

Authors:  Eileen A Forde; Rukiye-Nazan E Dogan; William J Karpus
Journal:  J Neuroimmunol       Date:  2011-05-14       Impact factor: 3.478

4.  Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Authors:  Liyanage P Perera; Meili Zhang; Masao Nakagawa; Michael N Petrus; Michiyuki Maeda; Marshall E Kadin; Thomas A Waldmann; Pin-Yu Perera
Journal:  Am J Hematol       Date:  2017-06-05       Impact factor: 10.047

5.  The role of alcohol on platelets, thymus and cognitive performance among HIV-infected subjects: are they related?

Authors:  María Jose Míguez-Burbano; Madhavan Nair; John E Lewis; Joel Fishman
Journal:  Platelets       Date:  2009-06       Impact factor: 3.862

6.  Blood flow patterns spatially associated with platelet aggregates in murine colitis.

Authors:  Lino F Miele; Aslihan Turhan; Grace S Lee; Miao Lin; Dino Ravnic; Akira Tsuda; Moritz A Konerding; Steven J Mentzer
Journal:  Anat Rec (Hoboken)       Date:  2009-08       Impact factor: 2.064

7.  Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.

Authors:  De-Kuan Chang; Jianhua Sui; Shusheng Geng; Asli Muvaffak; Mei Bai; Robert C Fuhlbrigge; Agnes Lo; Anuradha Yammanuru; Luke Hubbard; Jared Sheehan; James J Campbell; Quan Zhu; Thomas S Kupper; Wayne A Marasco
Journal:  Mol Cancer Ther       Date:  2012-08-06       Impact factor: 6.261

8.  Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis.

Authors:  C Y Ho; C K Wong; E K Li; L S Tam; C W K Lam
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 9.  Platelet chemokines in vascular disease.

Authors:  Christian A Gleissner; Philipp von Hundelshausen; Klaus Ley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-08-21       Impact factor: 8.311

10.  The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation.

Authors:  Risa Tamagawa-Mineoka; Norito Katoh; Eiichiro Ueda; Hideya Takenaka; Masakazu Kita; Saburo Kishimoto
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.